Clinical trials: Stage I Mantle Cell Lymphoma
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Anxiety Disorder, Cancer Survivor
Quality of Life in Younger Leukemia and Lymphoma Survivors
RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment.
- Conditions
- Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia
- Trial name
- NCT00956475
- Testing
- telephone-based intervention, questionnaire administration, assessment of therapy complications
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma, Thromboembolism
Heparin or Enoxaparin in Patients With Cancer
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor.
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004875
- Testing
- enoxaparin, heparin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
RATIONALE: Acupuncture may be effective in relieving mucositis-related pain caused by chemotherapy in patients undergoing stem cell transplantation.
- Trial name
- NCT00060021
- Testing
- acupuncture therapy, management of therapy complications, pain therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
PS-341 in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
- Trial name
- NCT00006362
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth…
- Trial name
- NCT00546377
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Mantle-Cell
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
The rationale for this study design is based on the fact that the maximum tolerated dose (MTD) of single-agent ofatumumab and bendamustine have been previously determined.
- Trial name
- NCT01221103
- Testing
- Combination of dexamethasone, ofatumumab and bendamustine
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Southern Europe New Drug Organization
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination works in treating patients with B-cell non-Hodgkin lymphoma that has…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT02281279
- Testing
- rituximab, lenalidomide, romidepsin
- Sponsor
- Mayo Clinic
Lymphoma
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab and yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00416312
- Testing
- Patient-specific dosimetry, conventional dosimetry
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma
- Trial name
- NCT00008216
- Testing
- Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Columbia University
Lymphoma
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Patients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16 patients (nodular, diffuse large cell, mantle cell plus…
- Trial name
- NCT00446095
- Testing
- fostamatinib
- Where
- 11 sites in United States
- Volunteers
- 81 people
- Sponsor
- Rigel Pharmaceuticals
Recurrent Mantle Cell Lymphoma
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
This phase I trial studies the side effects and best dose of ibrutinib and palbociclib in treating patients with previously treated mantle cell lymphoma.
- Trial name
- NCT02159755
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Palbociclib
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
The objective of this Phase I clinical trial is to evaluate the safety, toxicity profile, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of autologous CAR-T anti-CD19 cell therapy (CAR-T ANTI-CD19 COL01) in…
- Conditions
- Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL)
- Trial name
- COLIBRÍ (NCT07883941)
- Testing
- CAR-T anti-CD19 COL01
- Volunteers
- 12 people
- Sponsor
- GUSTAVO SALGUERO
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
This phase I trial studies the side effects and best dose of BTK inhibitor PCI-32765 when given together with rituximab and bendamustine hydrochloride in treating patients with recurrent non-Hodgkin lymphoma (NHL).
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT01479842
- Testing
- BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Kami Maddocks, MD
Chronic Myeloproliferative Disorders, Leukemia
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00800150
- Testing
- fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
This clinical trial studies personalized dose monitoring of busulfan and combination chemotherapy in treating patients with Hodgkin or non-Hodgkin lymphoma undergoing stem cell transplant.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT01959477
- Testing
- busulfan, etoposide, cyclophosphamide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Case Comprehensive Cancer Center